Recent Updates
Recently added Catalysts
TNDM Positive Sentiment

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Tandem Diabetes Care reported strong financial results for Q2 2026, with worldwide sales of $254.6 million, including $179.3 million from the U.S. The company achieved a gross margin of 57%, reflecting a significant increase from the previous year. Additionally, over 33,000 insulin pumps were shipped globally, showcasing the company's growth in the diabetes technology market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sales reached $254.6 million, indicating strong market demand.
  • Gross margin improved significantly by 460 basis points.
  • Over 33,000 pump shipments demonstrate robust product uptake.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.) Gross margin of 57%, up 460 basis points compared to second quarter 2025 Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in t

Frequently Asked Questions

What were Tandem's sales for Q2 2026?

Tandem Diabetes Care reported sales of $254.6 million for Q2 2026.

How much did Tandem earn in the U.S. for Q2 2026?

In the U.S., Tandem earned $179.3 million during Q2 2026.

What was the gross margin for Q2 2026?

Tandem's gross margin for Q2 2026 was 57%, up 460 basis points.

How many pumps did Tandem ship in Q2 2026?

Tandem shipped over 33,000 pumps worldwide in Q2 2026.

ShareAdd on Google
Tags: TNDM Viatris Investor Conferences Healthcare Tandem Diabetes Care financial results insulin delivery diabetes technology
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$570M liquidity · $0M/mo burn
Low dilution risk
Lead asset
tozadenantPhase 1
N/A, as Healthy Volunteers →